Abliva Q3’20: Energizing Interactions

Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Abliva Q3’20: Energizing Interactions

2020-11-23

07:20

NE

Niklas Elmhammer

Redeye believes the key takeaway from the recent quarter is the positive momentum in clinical and regulatory development for lead candidate KL1333. Abliva has also initiated preliminary discussions with a US clinical trial regarding a possible collaboration for non-core asset NeuroSTAT.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Abliva

0.254

▼ 0.01

-3.42%

Premium Plan required to unlock

Abliva

0.254

▼ 0.01

-3.42%

Premium Plan required to unlock